A study has highlighted the potential of graphene quantum dots in addressing the clumping of the 𝛂-synuclein protein, which is a critical factor in Parkinson's disease.
The research indicates that these quantum dots could provide a novel therapeutic approach to combatting the toxic aggregates linked to neurodegenerative conditions such as Parkinson's and multiple system atrophy.
This study was published on May 24, 2026, in Phys.org, marking a significant step in the exploration of innovative treatments for synucleinopathies.